Phase 2Active, not recruiting
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
A Multicenter, Dose-finding Study to Determine if Oral BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in Elderly Subjects
- Sponsor
- Restorbio Inc. (Industry)
- Enrolment
- 652 enrolled
- Conditions
- Respiratory Tract Infections
- Interventions
- Placebo; BEZ235; BEZ235 plus everolimus (RAD001)
- Ages
- older adults
- Registry
- NCT03373903
From the registry
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
Primary outcomes
- The percentage of subjects with 1 or more laboratory-confirmed RTIs through Week 16